Results 31 to 40 of about 14,668 (165)

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab [PDF]

open access: yes, 2020
18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM).
Chowdhury, Arnab   +51 more
core   +1 more source

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation

open access: yesTherapeutic Advances in Hematology, 2021
Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.
Chen-lu Yang   +4 more
doaj   +1 more source

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

open access: yesHaematologica, 2023
Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis is still challenging, and the prognosis remains very poor. Mayo stage IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with ...
Sara Oubari   +14 more
doaj   +1 more source

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

open access: yesHematology, Transfusion and Cell Therapy, 2021
Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM).
Edvan de Queiroz Crusoé   +7 more
doaj   +1 more source

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

open access: yesJournal of Translational Autoimmunity, 2019
Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent ...
Kristine A. Frerichs   +5 more
doaj   +1 more source

B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses

open access: yesLife Science Alliance, 2023
Daratumumab is an anti-CD38–targeting antibody that depletes plasma cells. This study shows that daratumumab also disturbs humoral immune responses beyond depletion only and may be used as therapeutic in B cell–mediated autoimmune diseases.
Dorit Verhoeven   +5 more
doaj   +1 more source

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2023
Background/Aims Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells.
Hee Jeong Cho   +17 more
doaj   +1 more source

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

open access: yesOncoImmunology, 2019
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity
Wojciech Dawicki   +7 more
doaj   +1 more source

Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)

open access: yesBlood Science
Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ monoclonal antibody targeting CD38, has shown good efficacy in the treatment of MM.
Gang An   +15 more
doaj   +1 more source

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

open access: yesHaematologica, 2023
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy ...
Luděk Pour   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy